Special Issue "Novel Therapeutic Approaches for Neurodegenerative Diseases Treatment, 2nd Edition"
Deadline for manuscript submissions: 10 November 2023 | Viewed by 652
Interests: bioactive compounds; cell signaling; drug delivery; drug discovery; enzymology; high-throughput screening; metalloproteases; molecular pharmacology; nanoparticles; neuropeptides; neurodegenerative diseases; parkinson's disease; protein-protein interaction inhibitors; protein engineering; protein structure; protease inhibitors; protein folding and aggregation; substrate specificity; X-ray crystallography
Special Issues, Collections and Topics in MDPI journals
Special Issue in Pharmaceutics: Bioactive Molecules from Plants: Discovery and Pharmaceutical Applications (Volume II)
Special Issue in Pharmaceutics: Novel Therapeutic Approaches for Neurodegenerative Diseases Treatment
Special Issue in Pharmaceutics: Bioactive Molecules from Plants: Discovery and Pharmaceutical Applications, 3rd Edition
Neurodegenerative disorders are typically characterized by the progressive loss of specific populations of neurons in the brain. They can be classified according to a variety of primary clinical features and are associated with characteristic molecular abnormalities. The most common neurodegenerative disorders are amyloidoses, tauopathies, α-synucleinopathies, and TDP-43 proteinopathies. Nearly all of these disorders are associated with the accumulation of protein deposits and with alterations in normal proteostasis. Despite recent advances in the field, most of the molecular mechanisms involved in disease progression are not completely understood. However, since protein aggregation is a central event in neurological disorders, a variety of novel approaches have been focused on developing novel pharmacologically active molecules targeting this process. In addition, our understanding of amyloid structures has been boosted by recent advances in the field of structural biology and cryo-EM; these advances have facilitated the recent elucidation of a large number of high-resolution amyloid structures associated with neurodegeneration. Without a doubt, such ground-breaking discoveries will facilitate the structure-based design of novel, functional, and specific protein aggregation inhibitors. Additionally, there is an increasing focus on the utilization of nanomaterials as efficient drug delivery systems targeting neurodegenerative disorders.
The focus of this Special Issue is on the development and identification of novel molecules and therapeutic approaches dedicated to treating neurodegenerative diseases. The topics include (but are not limited to) the following: the design and development of novel protein-aggregation inhibitors; drug delivery using nanotechnology; and the development and characterization of pharmacologically active compounds targeting proteostasis and neurodegeneration.
Dr. Javier Garcia-Pardo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- neurodegenerative diseases
- structure of amyloid fibrils
- protein aggregation
- Parkinson’s disease
- TDP-43 proteinopathies
- cell signaling
- drug discovery
- drug delivery
- high-throughput screening
- aggregation inhibitor
- protease inhibitor